Hat mitgewirkt an:
-
Identification and validation of a novel biologics target in triple negative breast cancer
-
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
-
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
-
Control of dataset bias in combined affymetrix cohorts of triple negative breast cancer